Vanguard Capital Management’s C4 Therapeutics CCCC Stock Holding History
Bought
Maintained
Sold
Other funds holding CCCC
LCM
Vanguard Capital Management's CCCC Position: Q3 2026 in Review
Vanguard Capital Management increased its C4 Therapeutics (CCCC) stake by 3.7% in Q3 2026, buying an estimated $611K and bringing the position to 4,581,502 shares worth $15.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2537.
Vanguard Capital Management first reported a position in CCCC in Q1 2026 and has held it in 3 quarters since. The position peaked at $20.6M in Q2 2026. 151 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.
- Vanguard Capital Management held 4,581,502 shares of C4 Therapeutics worth $15.3M as of Q3 2026.
- Vanguard Capital Management bought 163,771 C4 Therapeutics shares in Q3 2026, an estimated $611K.
- C4 Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2537 holding.
- Vanguard Capital Management first reported a position in C4 Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's C4 Therapeutics position peaked at $20.6M in Q2 2026.
- 151 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.